EGFR A767_V769dupASV

CI-VAR-00000135Explore in graph →CIViC 1579

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
EGFR A767_V769dupASV	Erlotinib	Predictive	C	Supports Resistance	—	accepted	EID4665 In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutations and treated with erlotinib monotherapy, patients with EGFR A767_V769dupASV mutation (n=3) experienced prog… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma6
EGFR A767_V769dupASV	Dacomitinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID12421 In an in vitro study, MCF-7 cells expressing the EGFR A767_V769dup mutation demonstrated sensitivity to dacomitinib (PF00299804), with YFP-EGFR-ICD relocation observed at 10 nM. In comparison, cells e… (full text at CIViC) PMID ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.